These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8418086)

  • 1. Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
    Spruss T; Bernhardt G; Schönenberger H; Engel J
    J Cancer Res Clin Oncol; 1993; 119(3):142-9. PubMed ID: 8418086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.
    Spruss T; Bernhardt G; Schickaneder E; Schönenberger H
    J Cancer Res Clin Oncol; 1991; 117(5):435-43. PubMed ID: 1890139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
    Spruss T; Schertl S; Schneider MR; Gust R; Bauer K; Schönenberger H
    J Cancer Res Clin Oncol; 1993; 119(12):707-16. PubMed ID: 8408183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum complexes with a selective action on estrogen receptor-positive mammary tumors.
    von Angerer E; Birnböck H; Knebel N
    Anticancer Drug Des; 1989 Jun; 4(1):21-35. PubMed ID: 2757751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cicaprost does not affect tumor inhibitory potential of cytostatic drugs.
    Schirner M; Schneider M
    Anticancer Res; 1993; 13(3):743-6. PubMed ID: 8317906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
    Karl J; Gust R; Spruss T; Schneider MR; Schönenberger H; Engel J; Wrobel KH; Lux F; Haeberlin ST
    J Med Chem; 1988 Jan; 31(1):72-83. PubMed ID: 3336035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
    Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
    Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.
    Reile H; Spruss T; Müller R; Gust R; Bernhardt G; Schönenberger H; Engel J
    Arch Pharm (Weinheim); 1990 May; 323(5):301-6. PubMed ID: 2383173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2001 Oct; 334(10):309-17. PubMed ID: 11759169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Dec; 333(12):397-403. PubMed ID: 11199469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
    Gust R; Karl J; Faderl M; Schönenberger H
    Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [1, 2-Bis(2, 6-difluoro-3-hydroxyphenyl)ethylene-diamine]platinum(II) complexes, compounds for the endocrine therapy of breast cancer - mode of action I: antitumor activity due to the reduction of the endogenous estrogen level.
    Schertl S; Hartmann RW; Batzl-Hartmann C; Bernhardt G; Spruss T; Beckenlehner K; Koch M; Krauser R; Schlemmer R; Gust R; Schönenberger H
    Arch Pharm (Weinheim); 2004 Jun; 337(6):335-48. PubMed ID: 15188223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of new murine breast cancer cell lines.
    Bernhardt G; Beckenlehner K; Spruss T; Schlemmer R; Reile H; Schönenberger H
    Arch Pharm (Weinheim); 2002 Mar; 335(2-3):55-68. PubMed ID: 12043456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.
    Beckenlehner K; Bannke S; Spruss T; Bernhardt G; Schönenberg H; Schiess W
    J Cancer Res Clin Oncol; 1992; 118(8):591-6. PubMed ID: 1517281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
    Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen.
    Darro F; Cahen P; Vianna A; Decaestecker C; Nogaret JM; Leblond B; Chaboteaux C; Ramos C; Pétein M; Budel V; Schoofs A; Pourrias B; Kiss R
    Breast Cancer Res Treat; 1998 Sep; 51(1):39-55. PubMed ID: 9877028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 2000 Mar; 333(2-3):69-71. PubMed ID: 10783521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.